Common use of Purchase Warrants Clause in Contracts

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date a warrant (“Representative’s Warrant”) for the purchase of an aggregate of [●] shares of Common Stock, representing 4.0% of the Firm Shares, for an aggregate purchase price of $100. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six (6) month after the Effective Date and expiring on the four and a half year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[●], which is equal to 120.0% of the initial public offering price of the Firm Shares. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant and the underlying shares of Common Stock during the one hundred eighty (180) day period after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrant, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date a warrant an option (“Representative’s Warrant”) for the purchase of an aggregate of [●·] shares of Common Stock, representing 4.04% of the shares of Common Stock underlying the Firm SharesUnits, for an aggregate purchase price of $100100.00. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six one (61) month year after the Effective Date and expiring on the four and a half five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock Share of $[●·], which is equal to 120.0125% of the initial public offering price of each Share underlying the Firm SharesUnits. The Representative’s Warrant Agreement and the shares of Common Stock Shares issuable upon exercise thereof are sometimes hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) day period first year after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantWarrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date a warrant (“Representative’s WarrantWarrants”) for the purchase of an aggregate of [●] 120,482 shares of Common Stock, representing 4.05.0% of the number of Firm Shares, for an aggregate purchase price of $100100.00. The agreement(s) representing the Representative’s Warrant agreementWarrants, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six (6) month months after the Effective Date and expiring on the four and a half five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[●]5.19, which is equal to 120.0125.0% of the initial public offering price of the Firm Shares. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant Agreement and the underlying shares of Common Stock during the one three hundred eighty sixty (180360) day period days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantWarrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one three hundred eighty sixty (180360) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date a warrant an option (“Representative’s Warrant”) for the purchase of an aggregate of [●] up to 89,999 shares of Common Stock, representing 4.05% of the Firm SharesPublic Securities, for an aggregate purchase price of $100100.00. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six one (61) month year after the Effective Date and expiring on the four and a half five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[●]12.50, which is equal to 120.0125% of the initial public offering price of the Firm Shares. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) day period days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantWarrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date a warrant an option (“Representative’s Warrant”) for the purchase of an aggregate of [●] shares Common Shares (which is equal to an aggregate of Common Stock, representing 4.03% of the Firm SharesShares excluding Company Shares sold in the Offering), for an aggregate purchase price of $100[ ]. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six one (61) month year after the Effective Date and expiring on the four and a half three-year anniversary of the Effective Date at an initial exercise price per share Common Share of Common Stock of $[●]$ , which is equal to 120.0125% of the initial public offering price of the each Firm SharesShare. The Representative’s Warrant Agreement and the shares of Common Stock Shares issuable upon exercise thereof are sometimes hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant Agreement and the underlying shares of Common Stock Shares during the one hundred eighty (180) day period days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantWarrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative Representatives (and/or its their designees) on the Closing Date a warrant an option (“Representative’s Representatives’ Warrant”) for the purchase of an aggregate of [●] up to 250,988 shares of Class B Common Stock, representing 4.07.5% of the Firm SharesShares and the Option Shares (if any), for an aggregate purchase price of $100100.00. The Representative’s Representatives’ Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Representatives’ Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six one (61) month year after the Effective Date and expiring on the four and a half five-year anniversary of the Effective Date at an initial exercise price per share of Class B Common Stock of $[●]6.325, which is equal to 120.0115% of the initial public offering price of the Firm Shares. The Representative’s Representatives’ Warrant Agreement and the shares of Class B Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Representatives’ Securities.” The Representative understands Representatives understand and agrees agree that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Representatives’ Warrant Agreement and the underlying shares of Class B Common Stock during the one hundred eighty (180) day period days after the Effective Date and by its acceptance thereof shall agree that it they will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantRepresentatives’ Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative Representatives or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date a warrant an option (“Representative’s Warrant”) for the purchase of an aggregate of [●•] shares of Common Stock, representing 4.05% of the shares of Common Stock underlying the Firm SharesUnits, for an aggregate purchase price of $100100.00. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six one (61) month year after the Effective Date and expiring on the four and a half five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock Share of $[●•], which is equal to 120.0125% of the initial public offering price of each share of Common Stock underlying the Firm SharesUnits. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are sometimes hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) day period first year after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantWarrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) 180 days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Purchase Warrants. The Company hereby agrees to issue and sell to the Representative Representatives (and/or its designees) on the Closing Date a warrant an option (“Representative’s Representatives’ Warrant”) for the purchase of an aggregate of [●•] shares of Common Stock, representing 4.03% of the Firm Shares (excluding the Additional Shares), for an aggregate purchase price of [$100100.00]. The Representative’s Warrant agreement, in the form attached hereto as Exhibit A (the “Representative’s Representatives’ Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is six one (61) month year after the Effective Date and expiring on the four and a half four-year anniversary of the Effective Date at an initial exercise price per share shares of Common Stock of $[●•], which is equal to 120.0125% of the initial public offering price of the Firm Shares. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representative’s Representatives’ Securities.” The Representative understands Representatives understand and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Representatives’ Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) day period days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s WarrantRepresentatives’ Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative Representatives or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.